Pharma — India Patent Cases
742 decisions indexed
Page 2 of 25 · 742 total
Merck Sharp & Dohme Corp. v.Ranvir Kumar Bindeshwari Singh
Merck Sharp & Dohme Corp. filed a suit seeking permanent injunction and damages against Ranvir Kumar Bindeshwari Singh for infringing Patent No. 209816, which covers SITAGLIPTIN. The court ultimately decreed the suit in favor of the plaintiffs, awarding substantial compensatory, exemplary, and costs damages.
Incyte Holdings Corporation v.Intas Pharmaceuticals Ltd
The suit was filed alleging infringement of Patent No. 269841 (IN'841) by Intas Pharmaceuticals Ltd regarding the compound Ruxolitinib. After discussions, the Defendant provided an undertaking that they would not commercialize the patented compound during the patent's validity. The court accepted this undertaking and disposed of the suit on consent terms.
Symrise Ag v.The Assistant Controller Of Patents And Designs
Symrise Ag filed an appeal challenging the Assistant Controller's decision to reject its patent application (No. 202117041016) for 'An Antimicrobial Mixture', holding that it was not patentable under specific sections of the Patents Act, 1970. The High Court issued notice and directed the respondent to file a reply within four weeks.
Saisun Pharma Pvt Ltd v.Novartis Ag & Anr.
Saisun Pharma Pvt Ltd filed a petition before the Delhi High Court. The petitioner submitted that a third-party post grant opposition had led to the revocation of the patent held by the respondents under Section 25(2) read with Section 25(4) of the Patent Act, 1970. Consequently, the court dismissed the present petition as infructuous.
M/S Coral Drugs Private Limited v.The Assistant Controller Of Patents And Designs and Anr
The appellant, M/S Coral Drugs Private Limited, filed an affidavit seeking leave from the Delhi High Court to amend its claims in a patent application. The company asserted that the amendments were lawful, bona fide, and did not broaden the original disclosure, but merely provided clarification.
Bayer Healthcare Llc v.Controller Of Patents And Designs & Ors.
Bayer Healthcare Llc filed an appeal seeking to set aside a previous order and obtain a patent for application number 1788/DELNP/2007. However, the appellant subsequently sought to withdraw the appeal on the ground that the patent term had expired.
Zydus Lifesciences Limited v.E. R. Squibb And Sons, Llc
Zydus Lifesciences appealed an injunction restraining it from selling its anti-cancer drug ZRC 3276, which was allegedly infringing E. R. Squibb's patent (5C4). The court considered the conflict between protecting IP rights and ensuring access to life-saving medication. Ultimately, the court modified the order by vacating the injunction but requiring Zydus to file audited accounts of sales until the patent expires.
Steigerwald Arzneimittlewerk Gmbh v.Assistant Controller Of Patents And Designs
The Appellant challenged the Assistant Controller's refusal to grant a patent application (No. 1285/DEL/2009) on grounds of lack of novelty and inventive step. The invention relates to a method for producing a plant-based medicament, Iberogast, which requires a specific mixing sequence for stable quality. The High Court found infirmities in the Controller's order regarding the reasoning under Sections 3(d) and 3(e), setting aside the Impugned Order and remanding the matter.
Helsinn Healthcare Sa v.Zydus Healthcare Limited
The plaintiffs filed an application seeking an ex parte ad interim injunction restraining the defendants from dealing in products that infringe their Indian Patent No. 426553, specifically mentioning the brand name NYKRON. The court accepted notice and directed the defendants to file a reply within two weeks.
E.R.Squibb & Sons Llc v.Union of India
E.R.Squibb & Sons LLC challenged the recommendation made by the Opposition Board regarding Patent No. IN340060, arguing that the board failed to consider crucial evidence submitted by the patentee during post-grant opposition proceedings initiated by Zydus Healthcare Limited. The Madras High Court dismissed the writ petition, holding that since the recommendation is only a suggestion for the Patent Authority, the petitioner could raise these objections during the final decision-making process or appeal.
Surface Logix Llc & Ors. v.Lucius Pharmaceutical Lucius Pharmaceutical(Lao) Co. Ltd & Ors.
Surface Logix LLC and its associates filed a suit seeking permanent injunction and damages against Lucius Pharmaceutical for alleged infringement of Indian Patent No. 291914, titled 'PHARMACOKINETICALLY IMPROVED COMPOUNDS'. The court addressed various procedural applications, including granting exemption from pre-litigation mediation due to the urgency of interim relief. Crucially, the court granted an ad-interim injunction restraining the defendants from infringing the patent and directed Defendant No. 2 (an online platform) to delist all advertisements related to the generic product 'BELUMOSUDIL' or brand name 'LuciBelu'.
Novartis A.G. v.YY
The Plaintiffs, Novartis A.G. and its affiliate, filed a suit seeking permanent injunction against the Defendant for infringing Indian Patent No. 419280. The court granted several interlocutory orders, including an interim injunction and exemption from mandatory pre-litigation mediation.
Myokardia Inc. v.Lucius Pharmaceutical
Myokardia Inc. filed a suit against Lucius Pharmaceutical alleging infringement of its Indian Patent No. 392872, which covers novel pyrimidinedione compounds used to treat serious cardiovascular diseases like hypertrophic cardiomyopathy (HCM). The Plaintiffs argued that the defendants' generic product infringed upon their patented technology and caused irreparable harm. Based on a prima facie assessment, the Delhi High Court granted an ex-parte ad-interim injunction restraining the defendants from manufacturing or selling generic Mavacamten until further hearing.
Incyte Holdings Corporation v.Sun Pharmaceutical Industries Limited
The plaintiffs filed a quia timet action alleging infringement of their patent (IN'841) covering the drug 'Ruxolitinib', marketed as JAKAVI®. The defendants denied commercialization and requested protection under Section 107A. Both parties agreed to settle, with the defendant undertaking not to commercially exploit the compound during the patent's validity.
Incyte Holdings Corporation v.Torrent Pharmaceuticals Limited
Incyte Holdings Corporation filed a quia timet action alleging that Torrent Pharmaceuticals Limited was about to infringe its Indian Patent No. 269841, which covers the compound Ruxolitinib (marketed as JAKAVI®). The parties reached an agreement where the defendant committed not to commercially manufacture or deal in products containing Ruxolitinib during the patent's validity, while retaining rights for research purposes.
Xx And Ors v.Yy
The suit was filed seeking permanent injunction restraining the defendant (Exemed Pharmaceuticals) from infringing the Indian Patent No. 269841, which covers the compound 'Ruxolitinib'. The court granted an interim injunction and passed various procedural orders related to the case.
Dr.Vishwanath Padmanabhan v.The Joint Controller of Patents & Designs, Head of Office, Patent Office Chennai
Dr. Vishwanath Padmanabhan challenged the Patent Office's decision to deem his invention application withdrawn under Section 11B(4) due to a technical uploading error in the e-filing portal. The court found that since the petitioner intended to proceed and had paid all requisite fees, the rejection was unjust.
Incyte Holdings Corporation v.Zydus Lifesciences Limited
The Delhi High Court passed several orders in CS(COMM) 1356/2025. The court granted exemption from pre-institution mediation due to the urgent nature of interim relief, allowed applications for discovery and additional documents, and addressed an ad-interim injunction request.
R P Scherer Technologies Llc v.The Patent Office of India
The petitioner challenged the rejection of its Indian Patent Application (No. 202127050600) by the Assistant Controller on grounds of lacking inventive step. The core issue was whether the claimed formulation for oral delivery of poorly permeable proteins/peptides was non-obvious over cited prior art. Given the technical nature, the Court appointed a Scientific Advisor to render an opinion.
Novo Nordisk A/S v.Dr Reddys Laboratories Limited & Anr.
Novo Nordisk A/S appealed an order where a Single Judge found infringement and granted limited relief to Dr Reddys Laboratories Limited. The appeal centers on whether the suit patent (IN 2626971) is vulnerable to invalidity under Section 64 of the Patents Act, given that the learned judge found the claim obvious from prior art.
Italfarmaco Spa v.Deputy Controller of Patents & designs
Italfarmaco Spa filed an appeal challenging the order passed by the Single Judge of the High Court of Madras. The core issue was whether this Original Side Appeal (OSA) was maintainable under Clause 15 of the Letters Patent, given that the underlying matter involved a decision made under Section 117A of the Patents Act, 1970. The court held that since the Commercial Courts Act is a special enactment and provides specific appeal mechanisms, the intra-Court Appeal under Clause 15 was not maintainable.
Incyte Holdings Corporation v.Natco Pharma Limited
The suit was filed by Incyte Holdings Corporation seeking permanent injunction against Natco Pharma Limited for infringing Indian Patent No. IN269841, which covers the compound 'Ruxolitinib'. During the proceedings, the defendant stated that they have not commercialized any infringing product and their activities are covered under Section 107-A of the Patents Act, 1970.
Incyte Holdings Corporation v.Bigbear Pharmaceutical (Lao) Co., Ltd
The Plaintiffs filed a suit seeking permanent injunction against the Defendants for infringing Indian Patent No. 269841 related to Ruxolitinib compounds. The court passed several orders granting exemptions from pre-institution mediation and advance service, and appointed Local Commissioners to inspect the alleged infringing activities.
Incyte Holdings Corporation v.Incepta Pharmaceuticals Ltd.
The Plaintiffs filed a suit seeking permanent injunction against Defendants for infringing Indian Patent No. 269841, which covers Ruxolitinib compounds (JAKAVI®). The court passed several orders granting exemptions to the Plaintiffs regarding mediation, identity masking, and advance service, while also directing the execution of Local Commissions to investigate the alleged infringement.
Incyte Holdings Corporation v.Lucius Pharmaceuticals Co., Ltd.
The Plaintiffs filed a suit seeking a permanent injunction to restrain the Defendants from infringing Indian Patent No. 269841 concerning Ruxolitinib Compounds. The court granted various exemptions sought by the plaintiffs, including exemption from pre-institution mediation, and proceeded with appointing Local Commissioners for the execution of the patent.
Novo Nordisk As v.Dr. Reddys Laboratories Limited & Anr.
Novo Nordisk filed a suit alleging infringement of its patent (IN'697) covering Semaglutide, a GLP-1 analogue used for diabetes and obesity. The Plaintiff sought an interim injunction to restrain the Defendants from importing or dealing in the compound. The Court ultimately dismissed the application, finding that the Plaintiff failed to establish a prima facie case for the grant of relief.
M/s. Shilpa Medicare Limited v.M/s. Salus Pharmaceutical & anr.
M/s. Shilpa Medicare Limited filed a commercial appeal against an order, seeking condonation of delay due to initial incorrect nomenclature. The court allowed the delay condonation, noting that procedural rules are handmaids of justice. Subsequently, the court set aside a single judge's order and remanded the matter for consideration on merits, emphasizing continuous infringement.
Medilabo Rfp Inc v.The Controller Of Patents
Medilabo Rfp Inc appealed the refusal of its patent application for a prophylactic drug composition intended for neurodegenerative diseases. The core dispute centered on whether the claims, which described a chemical composition, could be rejected under Section 3(i) (lack of inventive step/patentability criteria) because they were used for treatment. The High Court found that the Controller failed to address all objections and misinterpreted the scope of the product claim versus its therapeutic application. Consequently, the appeal was successful, leading to the setting aside of the refusal order and remanding the case for fresh consideration.
Amylin Pharmaceuticals, Llc And Anr v.Assistant Controller Of Patents And Designs
Amylin Pharmaceuticals appealed the Assistant Controller's rejection of its patent application for 'RELEASE FORMULATIONS USING NON-AQUEOUS CARRIERS'. The appeal challenged the finding that the invention lacked inventive step and fell under Section 3(d).
F. Hoffmann-La Roche Ag v.Zydus Lifesciences Limited
The Plaintiffs sought exemption from mandatory pre-litigation mediation. The Court disposed of this application as infructuous and noted that the current suit involves the same Suit Patent as another pending infringement suit (CS(COMM) 567/2024). Consequently, both suits were listed together for further proceedings.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.